KR20080061354A - 7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디히드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 무정형 고체분산체 - Google Patents

7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디히드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 무정형 고체분산체 Download PDF

Info

Publication number
KR20080061354A
KR20080061354A KR1020087004952A KR20087004952A KR20080061354A KR 20080061354 A KR20080061354 A KR 20080061354A KR 1020087004952 A KR1020087004952 A KR 1020087004952A KR 20087004952 A KR20087004952 A KR 20087004952A KR 20080061354 A KR20080061354 A KR 20080061354A
Authority
KR
South Korea
Prior art keywords
solid dispersion
therapeutically effective
effective amount
administering
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020087004952A
Other languages
English (en)
Korean (ko)
Inventor
어윈 씨. 제이콥스
존 디. 히긴스
미카엘 길롯
낸시 엠. 프란손
윌리암 엘. 로코
카울라 압둘라 아부-이짜
Original Assignee
사노피-아벤티스 유.에스. 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37499538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20080061354(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사노피-아벤티스 유.에스. 엘엘씨 filed Critical 사노피-아벤티스 유.에스. 엘엘씨
Publication of KR20080061354A publication Critical patent/KR20080061354A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020087004952A 2005-08-29 2006-08-24 7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디히드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 무정형 고체분산체 Abandoned KR20080061354A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215005P 2005-08-29 2005-08-29
US60/712,150 2005-08-29

Publications (1)

Publication Number Publication Date
KR20080061354A true KR20080061354A (ko) 2008-07-02

Family

ID=37499538

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087004952A Abandoned KR20080061354A (ko) 2005-08-29 2006-08-24 7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디히드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 무정형 고체분산체

Country Status (30)

Country Link
US (1) US7713548B2 (enExample)
EP (1) EP1926476B1 (enExample)
JP (1) JP5026426B2 (enExample)
KR (1) KR20080061354A (enExample)
CN (1) CN101272767B (enExample)
AR (1) AR055615A1 (enExample)
AU (1) AU2006285111B8 (enExample)
BR (1) BRPI0615609A2 (enExample)
CA (1) CA2619438A1 (enExample)
CR (1) CR9750A (enExample)
DK (1) DK1926476T3 (enExample)
EA (1) EA015715B1 (enExample)
EC (1) ECSP088203A (enExample)
ES (1) ES2414434T3 (enExample)
HN (1) HN2008000360A (enExample)
HR (1) HRP20130533T1 (enExample)
IL (1) IL189587A (enExample)
MA (1) MA29783B1 (enExample)
ME (1) ME01560B (enExample)
NO (1) NO20081364L (enExample)
NZ (1) NZ566313A (enExample)
PL (1) PL1926476T3 (enExample)
PT (1) PT1926476E (enExample)
RS (1) RS52914B (enExample)
SI (1) SI1926476T1 (enExample)
TN (1) TNSN08069A1 (enExample)
TW (1) TWI398250B (enExample)
UA (1) UA93517C2 (enExample)
WO (1) WO2007027494A2 (enExample)
ZA (1) ZA200801893B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2882684T3 (es) 2006-04-07 2021-12-02 Vertex Pharma Preparación de moduladores de transportadores del casete de unión a ATP
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
AU2009223014A1 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
AU2009283039A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4H-pyridazin0[4,5-b]indole-1-acetamide
ES2845449T3 (es) * 2010-03-25 2021-07-26 Vertex Pharma Dispersión sólida de forma amorfa de (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluoro-2(1-hidroxi-2-metilpropan-2-il)-1h-indol-5il)-ciclopropanocarboxamida
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
IN2012DE00674A (enExample) 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN105493092A (zh) * 2013-08-30 2016-04-13 慧与发展有限责任合伙企业 实时移动与模式分布的比较
WO2015141662A1 (ja) 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
PT3131582T (pt) 2014-04-15 2018-10-08 Vertex Pharma Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística
US10246461B2 (en) 2016-02-29 2019-04-02 Genentech, Inc. Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
UA127413C2 (uk) * 2017-07-04 2023-08-16 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція та спосіб її отримання

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091381A (en) * 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
FR2829939B3 (fr) * 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
EP1926476A2 (en) 2008-06-04
BRPI0615609A2 (pt) 2011-05-24
TW200727902A (en) 2007-08-01
CN101272767B (zh) 2012-08-29
AR055615A1 (es) 2007-08-29
TWI398250B (zh) 2013-06-11
CR9750A (es) 2008-06-18
US7713548B2 (en) 2010-05-11
EA015715B1 (ru) 2011-10-31
IL189587A (en) 2012-12-31
ME01560B (me) 2014-04-20
PL1926476T3 (pl) 2013-08-30
AU2006285111B8 (en) 2012-05-17
US20080160080A1 (en) 2008-07-03
MA29783B1 (fr) 2008-09-01
JP2009506114A (ja) 2009-02-12
PT1926476E (pt) 2013-07-10
ECSP088203A (es) 2008-06-30
HN2008000360A (es) 2011-05-31
NO20081364L (no) 2008-04-03
CN101272767A (zh) 2008-09-24
UA93517C2 (en) 2011-02-25
EP1926476B1 (en) 2013-04-10
AU2006285111A1 (en) 2007-03-08
SI1926476T1 (sl) 2013-07-31
WO2007027494A2 (en) 2007-03-08
AU2006285111B2 (en) 2012-04-26
TNSN08069A1 (en) 2009-07-14
CA2619438A1 (en) 2007-03-08
HK1124785A1 (en) 2009-07-24
NZ566313A (en) 2011-04-29
ZA200801893B (en) 2009-08-26
RS52914B (sr) 2014-02-28
EA200800713A1 (ru) 2008-10-30
IL189587A0 (en) 2008-08-07
ES2414434T3 (es) 2013-07-19
DK1926476T3 (da) 2013-07-01
WO2007027494A3 (en) 2007-08-02
HRP20130533T1 (en) 2013-07-31
JP5026426B2 (ja) 2012-09-12

Similar Documents

Publication Publication Date Title
US7713548B2 (en) Amorphous solid dispersions
US20250082645A1 (en) Irak4 degraders and uses thereof
KR101801424B1 (ko) 날부핀-기재 제제 및 그것의 용도
JP2013544230A (ja) 口腔内分散性製剤
JP2011515444A (ja) 固体分散体の調製方法
JP7190425B2 (ja) 肝細胞癌の治療のための併用療法
JP5464584B2 (ja) 抗ｈｉｖ化合物の臭化水素酸塩
JP2018516942A (ja) 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法
KR100930329B1 (ko) 6-머캅토퓨린의 개선된 제제
WO2021254409A1 (zh) 一种复合物的药物组合物及其制备方法
CN114557976B (zh) 一种灯盏花乙素缓释片及其制备方法
CN101429185A (zh) 槲皮素两种晶型物质、其制法和其药物组合物与用途
MX2008002988A (en) Morphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino [4, 5-b]indole-1-acetamide
HK1124785B (en) Amorphous solid dispersions of 7-chloro-n, n, 5-trimethyl-4-oxo-3-phenyl-3, 5-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide
CN117050029A (zh) 卡巴拉汀酒石酸盐与缬沙坦共无定型合物及制备方法和其组合物与用途
WO2009140479A1 (en) Amorphous solid dispersions
CN110452156B (zh) 多奈哌齐与厄贝沙坦共晶物及制备方法和其组合物与用途
WO2021226166A1 (en) Prodrug of itraconazole and use thereof
TR202019859A1 (tr) Emoksi̇pi̇n ve donepezi̇l i̇çeren farmasöti̇k formülasyonlar
KR20220088683A (ko) 치다미드 제약 조성물, 이의 제조 방법 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110624

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130320

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130905

PC1904 Unpaid initial registration fee